Search Result

Results for "

payload

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (26) ADC Antibody (2) ADC Linker (13) Antibody-Drug Conjugates (ADCs) (13) Apoptosis (4) Autophagy (2) Bacterial (2) Biochemical Assay Reagents (3) c-Met/HGFR (1) DNA Alkylator/Crosslinker (5) Drug Intermediate (3) Drug Metabolite (2) Drug-Linker Conjugates for ADC (25) EGFR (3) Elastase (1) FGFR (1) GCGR (2) Glucocorticoid Receptor (1) IFNAR (1) Integrin (1) Isotope-Labeled Compounds (1) Liposome (10) Mesothelin (1) Microtubule/Tubulin (10) Mucin (1) NAMPT (3) P-glycoprotein (1) PD-1/PD-L1 (1) PROTAC Linkers (1) PSMA (1) Src (1) STING (1) Target Protein Ligand-Linker Conjugates (1) Toll-like Receptor (TLR) (1) Topoisomerase (5)
By Research Areas:	Cancer (88) Infection (1) Inflammation/Immunology (4) Metabolic Disease (3) Neurological Disease (1)
Click Chemistry:	ADC Synthesis (1) DBCO (2)
Oligonucleotides:	Pegylated Lipids (1)

107

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Targets Recommended: ADC Cytotoxin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P10736A

*AMG133 peptide payload* TFA**	GCGR	Metabolic Disease
AMG133 peptide payload TFA is the TFA salt form of AMG133 peptide payload (HY-P10736). AMG133 peptide payload TFA is a GLP-1 agonist that can be used for synthesis of Maridebart cafraglutide (AMG133) (HY-164535) as a peptide linker conjugate .

HY-148128

TAM470	Microtubule/Tubulin ADC Cytotoxin	Cancer
TAM470 is a novel cytolysin, inhibiting tubulin polymerization and microtubule depolymerization. TAM470 can be used in the synthesis of OMTX705 as payload molecule, OMTX705 is a novel FAP-targeting antibody-drug conjugates (ADCs) with antitumor activity .

HY-147193

Nampt-IN-10 TFA	NAMPT	Cancer
Nampt-IN-10 TFA (compound 4) is a Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitor. Nampt-IN-10 TFA shows cellular potency to A2780 and CORL23 cells lines with IC₅₀s of 5 and 19 nM, respectively. Nampt-IN-10 TFA can be used as a novel non-antimitotic payload for ADCs .

HY-P10736

AMG133 peptide payload	GCGR	Metabolic Disease
AMG133 peptide payload is a GLP-1 agonist that can be used as a peptide linker conjugate of Maridebart cafraglutide (AMG133) (HY-164535) .

HY-164787

N-MeVal-Val-Dil-Dap-2-(pyridin-3-yl)ethanamine	ADC Cytotoxin Microtubule/Tubulin	Cancer
N-MeVal-Val-Dil-Dap-2-(pyridin-3-yl)ethanamine (Compound 14) is a tubulin polymerization inhibitor that can be used as an ADC payload .

HY-156249

NMS-P528	ADC Cytotoxin	Cancer
NMS-P528 is a Duocarmycin derivative that can be used as an ADC payload. NMS-P528 can be used to synthesize NMS-P945 .

HY-160597

Exatecan-amide-bicyclo[1.1.1]pentan-1-ol	ADC Cytotoxin Topoisomerase	Cancer
Exatecan-amide-bicyclo[1.1.1]pentan-1-ol (Compound 79) is an exatecan (HY-13631) derivative that can be used as a payload in drug conjugates. Exatecan-amide-bicyclo[1.1.1]pentan-1-ol has significant inhibitory activity against a variety of tumor cell lines .

HY-135901

Py-MPB-amino-C3-PBD	ADC Cytotoxin Bacterial	Cancer
Py-MPB-amino-C3-PBD is a cytotoxic agent comprised non-alkylating group. Py-MPB-amino-C3-PBD acts as the payload for ADCs. Antimicrobial activity .

HY-132158

MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin	Drug-Linker Conjugates for ADC	Cancer
MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin (compound 21a), a camptothecin payload, can be conjugated to a monoclonal antibody (mAb) for the synthesis of camptothecin antibody-drug conjugate (ADC) .

HY-135900

Aniline-MPB-amino-C3-PBD	ADC Cytotoxin Bacterial	Cancer
Aniline-MPB-amino-C3-PBD is a cytotoxic agent comprised non-alkylating group. Aniline-MPB-amino-C3-PBD is a sequence-selective DNA minor-groove binding agent. Aniline-MPB-amino-C3-PBD acts as the payload for ADCs. Antimicrobial activity .

HY-141600

Aprutumab ixadotin BAY 1187982	Antibody-Drug Conjugates (ADCs) FGFR Microtubule/Tubulin Apoptosis	Cancer
Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully human anti-FGFR2 monoclonal antibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer .

HY-139441

DM21	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
DM21 is a next-generation linker-payload that combines a maytansinoid microtubule-disrupting payload with a stable tripeptide linker. DM21 is conjugated with a humanized antibody against ADAM9 to obtain IMGC936 .

HY-107502

Cryptophycin analog 1	Antibody-Drug Conjugates (ADCs)	Cancer
Cryptophycin analog 1 is an ADC payload. Cryptophycin analog 1 shows anticancer activity. Cryptophycin analog 1 displays cell activity an order of magnitude more potent than approved ADC payloads MMAE and DM1 .

HY-15581

MMAD Demethyldolastatin 10; Monomethylauristatin D; Monomethyl Dolastatin 10	Microtubule/Tubulin ADC Cytotoxin	Cancer
MMAD is a potent tubulin inhibitor, is a toxin payload in antibody agent conjugates (ADCs).

HY-132162

7-MAD-MDCPT	ADC Cytotoxin	Cancer
7-MAD-MDCPT, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs) .

HY-156756

7-Hydroxymethyl-10,11-MDCPT	ADC Cytotoxin	Others
7-Hydroxymethyl-10,11-MDCPT is a payload that can be used for ADC synthesis .

HY-160512

Lipid 9	Liposome	Others
Lipid 9 is an ionizable lipid that can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads .

HY-101127

SGD-1882 PBD dimer	ADC Cytotoxin	Cancer
SGD-1882 is a cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, acting as the payload for ADCs.

HY-126663

N-Me-L-Ala-maytansinol	ADC Cytotoxin	Cancer
N-Me-L-Ala-maytansinol is a hydrophobic, cell permeable payload used for making antibody-drug conjugate (ADC) .

HY-164429

VIP236	Integrin Elastase	Cancer
VIP236 is a small-molecule-drug conjugates (SMDCs) consisting of an αvβ3 integrin binder linked to an optimized Camptothecin (HY-16560) topoisomerase I (TOP1) inhibitor payload. VIP236 exerts anticancer activity by targeting αvβ3 integrins, and it can release payload upon cleavage by neutrophil elastase in the tumor microenvironment .

HY-163672

Glucocorticoid receptor modulator 3	Glucocorticoid Receptor	Metabolic Disease Inflammation/Immunology
Glucocorticoid receptor modulator 3 (Payload 6) is a thioester-containing glucocorticoid receptor modulator (IC₅₀=0.6 nM). Glucocorticoid receptor modulator 3 is designed to inactivate unconjugated payloads rapidly through liver metabolism, thereby minimizing systemic exposure. Glucocorticoid receptor modulator 3 can be utilized in the development of antibody-drug conjugates (ADCs) targeting autoimmune diseases .

HY-164707

MC7	Drug-Linker Conjugates for ADC	Cancer
MC7 is a drug-linker conjugate for ADC and can be used for ADC synthesis. The payload is a NAMPT inhibitor (HY-402237) .

HY-164705

Mal-Toxophore	Drug-Linker Conjugates for ADC	Cancer
Mal-Toxophore is a drug-linker conjugate for ADC and can be used for ADC synthesis. The payload is a NAMPT inhibitor (HY-164759) .

HY-159865

CL15F6	Liposome	Others
CL15F6 is an ionizable lipid that can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads .

HY-159862

IM21.7c	Liposome	Infection
IM21.7c is a cationic lipid that can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads .

HY-101141

sulfo-SPDB-DM4	Drug-Linker Conjugates for ADC	Cancer
sulfo-SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, an antitubulin agent) via the sulfo-SPDB linker.

HY-159853

C14-A1	Liposome	Inflammation/Immunology
C14-A1 is an ionizable cationic lipid that can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads .

HY-159854

C14-O2	Liposome	Cancer
C14-O2 is an ionizable cationic lipid that can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads .

HY-169324

APL-1092 Mal-Exo-EEVC-Exatecan	Drug-Linker Conjugates for ADC	Cancer
APL-1092 (Mal-Exo-EEVC-Exatecan) is a drug-linker conjugate for ADC, which contains Exatecan (HY-13631) (ADC payload) and a linker .

HY-164730

Epratuzumab Tesirine ADCT-602; hLL2-Cys-PBD	Antibody-Drug Conjugates (ADCs)	Cancer
Epratuzumab Tesirine (ADCT-602) is a novel CD22-targeted ADC. Epratuzumab Tesirine contains a PBD dimer and a payload SG3249 .

HY-117371

Hemiasterlin (-)-Hemiasterlin; Milnamide B	ADC Cytotoxin	Cancer
Hemiasterlin ((-)-Hemiasterlin) is an antimitotic marine natural product with potent anticancer effcts. Hemiasterlin can be used as a cytotoxic payload (ADC Cytotoxin) in antibody-drug conjugates (ADCs) .

HY-128952

Tesirine 3 Publications Verification SG3249	Drug-Linker Conjugates for ADC DNA Alkylator/Crosslinker	Cancer
Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .

HY-159855

CAP 2 hydrochloride Cholesterol-amino-phosphate 2 hydrochloride	Liposome	Others
CAP 2 (Cholesterol-amino-phosphate 2) hydrochloride is Cholesterol-amino-phosphate (CAP) lipid. CAP 2 can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads .

HY-101161

SG3199 2 Publications Verification	DNA Alkylator/Crosslinker ADC Cytotoxin	Cancer
SG3199 is a cytotoxic DNA minor groove interstrand crosslinking pyrrolobenzodiazepine (PBD) dimer. SG3199 is the released warhead component of the ADC payload Tesirine (SG3249) .

HY-12460

SPDB-DM4	Drug-Linker Conjugates for ADC	Cancer
SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, a tubulin inhibitor) via a SPDB linker, exhibiting potent anti-tumor activity.

HY-159856

16:0 Cardiolipin Diphosphatidylglycerol (16:0)	Liposome	Others
16:0 Cardiolipin (Diphosphatidylglycerol (16:0)) is a phospholipid derived from Palmitic acid (16:0) that can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads .

HY-153909

SMP-33693	Drug-Linker Conjugates for ADC	Cancer
SMP-33693 is a Drug-Linker Conjugate for ADC with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .

HY-W800621

Fmoc-PEG2-Val-Cit-PAB-OH	ADC Linker	Cancer
Fmoc-PEG2-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Fmoc protecting group may be removed with piperidine to reveal a primary amine for use in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.

HY-W800622

Fmoc-PEG4-Val-Cit-PAB-OH	ADC Linker	Cancer
Fmoc-PEG4-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Fmoc protecting group may be removed with piperidine to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.

HY-W800625

Boc-PEG4-Val-Cit-PAB-OH	ADC Linker	Cancer
Boc-PEG4-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Boc protecting group may be removed with acid to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.

HY-W800623

Fmoc-PEG6-Val-Cit-PAB-OH	ADC Linker	Cancer
Fmoc-PEG6-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Fmoc protecting group may be removed with piperidine to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.

HY-W800624

Boc-PEG2-Val-Cit-PAB-OH	ADC Linker	Cancer
Boc-PEG2-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Boc protecting group may be removed with acid to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.

HY-153908

SMP-93566	Drug-Linker Conjugates for ADC	Cancer
SMP-93566 is a kind of antibody-drug conjugates (ADCs) with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .

HY-164706

m-PEG6-Lys-Mal-Toxophore-quinoline	Drug-Linker Conjugates for ADC	Cancer
m-PEG6-Lys-Mal-Toxophore-quinoline is a drug-linker conjugate for ADC and can be used for ADC synthesis. The payload is a NAMPT inhibitor (HY-164760) .

HY-145663

HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM	Drug-Linker Conjugates for ADC	Cancer
HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM is a agent-linker (peptide-cleavable) conjugate for ADC. DM indicates the maytansinoid moiety .

HY-145078

PNU-EDA-Gly5	Drug-Linker Conjugates for ADC	Cancer
PNU-EDA-Gly5 is an oligo-glycine linker-payload for ADC synthesis, composed of a DNA topoisomerase I inhibitor PNU-159682 and a linker EDA-Gly5 .

HY-171269

Anetumab-MMAE	ADC Antibody Mesothelin	Cancer
Anetumab-MMAE is an antibody-drug conjugate (ADC) (Anetumab antibody (HY-P99352), Linker: VC linker, Payload: MMAE (HY-15162)). Anetumab is an anti-mesothelin (MSLN) antibody.

HY-W591449

DOPE-PEG-Azide, MW 2000	Liposome	Cancer
DOPE-PEG-Azide, MW 2000 is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .

HY-153725

17:1 Lyso PC	Liposome	Cancer
17:1 Lyso PC is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .

HY-171159

MC-Val-Cit-PAB-Sunitinib	Target Protein Ligand-Linker Conjugates	Neurological Disease
MC-Val-Cit-PAB-Sunitinib is the conjugate of a payload Sunitinib (HY-10255A) and a linker. MC-Val-Cit-PAB-Sunitinib can be used for synthesis of HR97-Sunitinib .

Cat. No.	Product Name

HY-L023

Toxins for Antibody-Drug Conjugate Research Library

113 compounds

Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide.

The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 113 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.

Cat. No.	Product Name	Target	Research Area

HY-P10736A

*AMG133 peptide payload* TFA**	GCGR	Metabolic Disease
AMG133 peptide payload TFA is the TFA salt form of AMG133 peptide payload (HY-P10736). AMG133 peptide payload TFA is a GLP-1 agonist that can be used for synthesis of Maridebart cafraglutide (AMG133) (HY-164535) as a peptide linker conjugate .

HY-P10736

AMG133 peptide payload	GCGR	Metabolic Disease
AMG133 peptide payload is a GLP-1 agonist that can be used as a peptide linker conjugate of Maridebart cafraglutide (AMG133) (HY-164535) .

Cat. No.	Product Name	Target	Research Area

HY-141600

Aprutumab ixadotin BAY 1187982	Antibody-Drug Conjugates (ADCs) FGFR Microtubule/Tubulin Apoptosis	Cancer
Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully human anti-FGFR2 monoclonal antibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer .

HY-P99813

Patritumab deruxtecan HER3-DXd; U3-1402	Antibody-Drug Conjugates (ADCs)	Cancer
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .

HY-P99829

Cofetuzumab pelidotin PF-06647020; ABBV-647; h6M24-vc0101	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101; HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC₅₀ of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research .

HY-P991294

MGTA-117 Antibody	ADC Antibody	Cancer
MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-117371

Hemiasterlin (-)-Hemiasterlin; Milnamide B	Alkaloids Structural Classification Classification of Application Fields Animals Marine natural products Sponge Disease Research Fields Indole Alkaloids Cancer	ADC Cytotoxin
Hemiasterlin ((-)-Hemiasterlin) is an antimitotic marine natural product with potent anticancer effcts. Hemiasterlin can be used as a cytotoxic payload (ADC Cytotoxin) in antibody-drug conjugates (ADCs) .

HY-13704

SN-38 45+ Cited Publications 7-Ethyl-10-hydroxycamptothecin	Alkaloids Structural Classification Classification of Application Fields Labiatae Samanea saman (Jacq.) Merr. Source classification Quinoline Alkaloids Plants Disease Research Fields Cancer	Drug Metabolite Topoisomerase ADC Cytotoxin Autophagy
SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis with IC₅₀s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254) .

HY-13704R

SN-38 (Standard)	Alkaloids Structural Classification Labiatae Samanea saman (Jacq.) Merr. Source classification Quinoline Alkaloids Plants	Drug Metabolite Topoisomerase ADC Cytotoxin Autophagy
SN-38 (Standard) is the analytical standard of SN-38. This product is intended for research and analytical applications. SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254) .

Cat. No.	Product Name	Chemical Structure

HY-156756S

7-Hydroxymethyl-10,11-MDCPT-d5
7-Hydroxymethyl-10,11-MDCPT-d₅ is deuterium labeled 7-Hydroxymethyl-10,11-MDCPT, which is a is a payload that can be used for ADC synthesis .

Cat. No.	Product Name		Classification

HY-147363

DIBAC-GGFG-NH2CH2-Dxd		DBCO ADC Synthesis
DIBAC-GGFG-NH2CH2-Dxd (compound LP4), a Camptothecin (HY-16560) derivative, is a linker-payload of protein-agent conjugates . Dxd (HY-13631D) can be used as a payload for the antibody-coupling drug ADC (DS-8201a).DIBAC-GGFG-NH2CH2-Dxd is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups .

HY-126690

DBCO-(PEG2-VC-PAB-MMAE)2		DBCO
DBCO-(PEG2-VC-PAB-MMAE)2 is made by MMAE conjugated to the cleavable DBCO-(PEG2-VC-PAB)2 linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody agent conjugate . DBCO-(PEG2-VC-PAB-MMAE)2 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

Cat. No.	Product Name		Classification